Etiology of fatal infections
| . | n . |
|---|---|
| Fatal infections | 79 |
| Microbiologically confirmed | 42 (53% of fatal infections) |
| Viral | 32 (41% of fatal infections) |
| SARS-CoV-2 | >29∗ |
| EBV | 1 |
| CMV | 1† |
| PML | 1 |
| Bacterial | 4 (5% of fatal infections) |
| Gram-negative bacteremia | 4 |
| Fungal | 5 (6% of fatal infections) |
| Candidemia | 1 |
| Pneumocystis jirovecii pneumonia | 3 |
| Systemic mycoses | 1 |
| Protozoan | |
| Toxoplasmosis | 1 |
| Clinically diagnosed | 12 (15% of fatal infections) |
| Sepsis | 4 |
| Pneumonia | 8 |
| Etiology not reported | 25 (32% of total infections) |
| . | n . |
|---|---|
| Fatal infections | 79 |
| Microbiologically confirmed | 42 (53% of fatal infections) |
| Viral | 32 (41% of fatal infections) |
| SARS-CoV-2 | >29∗ |
| EBV | 1 |
| CMV | 1† |
| PML | 1 |
| Bacterial | 4 (5% of fatal infections) |
| Gram-negative bacteremia | 4 |
| Fungal | 5 (6% of fatal infections) |
| Candidemia | 1 |
| Pneumocystis jirovecii pneumonia | 3 |
| Systemic mycoses | 1 |
| Protozoan | |
| Toxoplasmosis | 1 |
| Clinically diagnosed | 12 (15% of fatal infections) |
| Sepsis | 4 |
| Pneumonia | 8 |
| Etiology not reported | 25 (32% of total infections) |
CMV, cytomegalovirus; EBV, Epstein-Barr virus; PML, Progressive Multifocal Leukoencephalopathy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Some studies reported at least the proportion or total number of SARS-CoV-2 associated deaths, thus the acutal number may be higher.
After first-line therapy.